ArticleJournal of maxillofacial and oral surgery2024
Deciphering Annona's Anticancer Potential: Comparative Analysis of Crude Extract Versus Nanoformulation on SCC-25 Oral Cancer Cells Through cell Viability, Apoptosis, Cell Cycle, ROS, and MMP Analysis.
Article in Journal of maxillofacial and oral surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cytotoxic and apoptotic effects of novel phytochemical extracts on oral squamous cell carcinoma cells.Bioinformation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Annona muricata contains acetogenins, which have shown promising anticancer activity against various cell lines. This study aims to evaluate and compare the anticancer activity of the crude extract of Annona muricata and its nano formulation on Squamous Cell Carcinoma-25 (SCC-25) oral cancer cell lines. Methods: The crude extract of Annona muricata was prepared using standard extraction techniques, while its nano formulation was synthesized through nanoparticle fabrication methods. Authenticated SCC-25 cell lines were obtained from ATCC and cultured and treated with varying concentrations of both the crude extract and nano formulation. Cell viability assays, apoptosis assays, Cell Cycle assay, ROS, and MMP analysis techniques were employed to assess the anticancer activity and mechanism of action. Results: In the MTT assay, the Annona formulation treated cells exhibited lower IC50 values compared to the crude extract treated SCC-25 cell lines. In the cell cycle assay, the Annona crude extract induced higher cell cycle arrest in the G1 phase in SCC-25 cell lines compared to the control. The nano formulation of Annona demonstrated significantly higher cell cycle arrest in G1 phase compared to both the control and the Annona crude extract-treated SCC-25 cell lines. The crude extract showed less apoptotic activity in apoptosis assay when compared to control, whereas the Annona formulation exhibited higher late apoptosis compared to the control, indicating the potential anticancer properties of Annona. The mean fluorescent intensity test of SCC-25 oral cancer cells treated with Annona crude extract and Annona formulation showed a significant loss of Mitochondrial membrane potential compared to the control. The percentage of MMP was lower in Annona-treated cells, while the Annona formulation treated cells showed similar results to the control. The mean fluorescent intensity of ROS in SCC-25 oral cancer cells treated with Annona crude extract and Annona formulation showed significantly lower Reactive oxygen species production compared to the control. The percentage of ROS was lower in Annona treated cells compared to the formulation, but the Annona formulation-treated cells showed lower values than the control. Conclusion: In conclusion, both the crude extract and nano formulation of Annona muricata possess potent anticancer activity against SCC-25 oral cancer cell lines. However, the nano formulation exhibited superior efficacy, suggesting its potential for further development as a therapeutic agent for oral cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.